AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 242 min read$COR

Tyler Lauren M purchased $149K of COR

Tyler Lauren M purchased 550 shares of Cencora, Inc. (COR) at $270.23 ($0.15M total) on 2026-06-22.

Original reporting
SEC EDGAR · Tyler Lauren M
Published Jun 24, 2026, 8:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$COR
Bullish
low confidence
Mentioned
$COR
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORBullishLow
01

Why it matters

The newest fact is the director’s open-market purchase details (550 shares at $270.23; ~$148.6K total). This can marginally support sentiment but does not change earnings, guidance, or risk materially.

02

Market read

Useful for tracking insider activity, but the transaction size and lack of fundamental updates make it low-conviction for trading decisions.

03

What to watch

No 10b5-1 plan is noted, but the article provides no context on prior holdings, motivation, or whether other insiders made similar moves.

Relevance 5/10Novelty 5/10Timing: SEC Form 4 filed 2026-06-24 (transaction dated 2026-06-22).

Background

The article is an SEC Form 4 insider transaction disclosure for Cencora, Inc. (COR).

Company-level read

Ticker impact

$CORBullishLow confidence
Context

Cencora (COR) disclosed via SEC Form 4 that director Tyler Lauren M bought 550 shares at $270.23 on 2026-06-22 for ~$148.6K.

Expected impact

Likely limited near-term price impact; any effect is small and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 insider transaction with no 10b5-1 plan and no accompanying company-specific operational or financial update.

Market effects

Sector

Minimal; insider buying at a single healthcare distributor does not materially change sector fundamentals.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider purchases can be discretionary, tax/portfolio-driven, or small relative to typical trading volumes, so they may not reflect a new view on fundamentals.

Key entities

  • public_company
    Cencora, Inc.

    Issuer of the Form 4 insider transaction; director Tyler Lauren M purchased shares.

  • insider
    Tyler Lauren M

    Director who reported an open-market purchase of 550 shares on 2026-06-22.

Read at source← All news

Related articles

AUG 8
$CORMed

The Bull Case For Cencora (COR) Could Change Following Raised EPS Outlook And Bigger Buybacks And Dividend

Cencora (COR) reported Q3 2026 sales of $84.75B and net income of $763.5M, and amended credit and receivables facilities, expanding revolving capacity to $7.0B. The company raised its fiscal 2026 adjusted EPS outlook, completed a $2.0B buyback tranche, and declared a $0.60 quarterly dividend. It flagged a possible earnings headwind tied to an MWI Animal Health-Covetrus merger.

simplywall.st4 min
AUG 7
$CORMedAI 8/10

Cencora Q3 Earnings Call Highlights

Cencora (NYSE:COR) reported Q3 results on its earnings call. U.S. Healthcare Solutions operating income rose 16% to $966 million, and International revenue grew 6% to $7.7 billion with operating income up 21% to $166 million. The company expects fiscal 2026 consolidated adjusted operating income growth of 13% to 14%, and said OneOncology integration is modestly ahead of initial expectations.

yahoo.com6 min
AUG 7
$CORMed

Cencora, Inc. Q3 2026 Earnings Call Summary

Cencora reported Q3 2026 results driven by specialty pharmaceutical strength in health systems and physician practices, with its MSO platforms (including OneOncology and RCA) ahead of expectations. Adjusted EPS guidance for fiscal 2026 was raised to $17.75 to $17.95. The company completed $1 billion of share repurchases, expects U.S. Healthcare Solutions revenue in the lower half of 4% to 6% growth, and cited a $0.35 EPS headwind from the pending MWI Animal Health merger.

yahoo.com7 min
AUG 5
$CORHigh

Cencora, Inc. (COR): Results of Operations and Financial Condition

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q32026.htm EX-99.1 Document Exhibit 99.1 CENCORA REPORTS FISCAL 2026 THIRD QUARTER RESULTS Revenue of $84.8 billion for the Third Quarter, a 5.1 percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $3.94 and Adjusted Diluted EPS of $4.48 Adjusted

SEC EDGAR 8-K4 min